Drug-Eluting Stents, Bare-Metal Stents, and Bypass Surgery

Data from two studies suggest that when considering PCI, the setting matters more than the stent.

Drug-eluting stents (DES) are frequently used in off-label situations. Two new observational studies illuminate the real-world use of DES.

In the first study, investigators used data from the National Heart, Lung, and Blood Institute (NHLBI) Dynamic Registry to compare the safety and efficacy of DES versus bare-metal stents (BMS) for manufacturer-approved versus off-label indications. The off-label group (1312 DES recipients and 2110 BMS recipients) included patients with lesions that were restenotic; in bypass grafts; in long (>30 mm), small, and large vessels; at ostial, left main, and bifurcation locations; and totally occluded. DES recipients had longer and more complex lesions than BMS recipients and also were more likely to be receivin…

Reviewing Author

Howard C. Herrmann, MD

Disclosures

Consultant/Advisory BoardAffluent Medical; Artedrone; Caranx; Johnson & Johnson; Medtronic; Prolifagen; Wells Fargo

EquityMicrointerventional Devices, Inc.

RoyaltiesUniversity of Pennsylvania

Grant/Research SupportAbbott Vascular; Edwards Lifesciences; Johnson & Johnson; Medtronic

Editorial BoardsCatheterization and Cardiovascular Interventions; Journal of the American College of Cardiology; Circulation: Cardiovascular Interventions; JACC Cardiovascular Interventions; JACC Case Reports; JSCAI